Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GLA | P06280 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL444569 | 0.83 | KMT2A (0.46) | ALDH1A1HPGDMAPTGLAACHE | |
| SCHEMBL444814 | 0.83 | KMT2A (0.46) | ALDH1A1HPGDMAPTGLAACHE | |
| SCHEMBL10573026 | 0.77 | ALDH1A1 (0.54) | ALDH1A1HPGDMAPTGLAACHE | |
| SCHEMBL444874 | 0.75 | MEN1 (0.46) | ALDH1A1HPGDMAPTGLAACHE | |
| SCHEMBL28981243 | 0.75 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPTGLAACHE | |
| SCHEMBL9572104 | 0.72 | ALDH1A1 (0.48) | ALDH1A1HPGDMAPTGLAACHE | |
| SCHEMBL452908 | 0.72 | NPC1 (0.49) | ALDH1A1HPGDMAPTGLAACHE | |
| SCHEMBL30645420 | 0.72 | NPC1 (0.49) | ALDH1A1HPGDMAPTGLAACHE | |
| SCHEMBL3506845 | 0.72 | NPC1 (0.49) | ALDH1A1HPGDMAPTGLAACHE | |
| Hydrochloric Acid SCHEMBL4353079 | 0.71 | NPC1 (0.48) | ALDH1A1HPGDMAPTGLAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233409-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2019-08-01 | — | — | US | disclosed |
| US-9655886-B2 | Substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, methods for use thereof | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170000773-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-01-05 | — | — | US | disclosed |
| EP-2145887-B1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR THE PRODUCTION AND USE THEREOF | ALLA CHEM LLC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| EP-1937652-B1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMA INC (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2368877-B1 | Peptidomimetic protease inhibitors and intermediates for their preparation As treatment for HCV infection | VERTEX PHARMA (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-1958956-B1 | Peptidomimetic protease inhibitors | VERTEX PHARMA (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8541437-B2 | Substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, methods for the production and use thereof | ALLA CHEM, LLC (US) | 2013-09-24 | — | — | US | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| WO-2000040547-A1 | α-SUBSTITUTION OF UNPROTECTED β-AMINO ESTER COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-1999067192-A2 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND α,β-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999048870-A1 | PIPERIDIDINYL AND N-AMIDINOPIPERIDINYL DERIVATIVES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999038844-A1 | METHOD FOR PREPARING AN N-[(ALIPHATIC OR AROMATIC)CARBONYL]-2-AMINOACETAMIDE COMPOUND AND A CYCLYZED COMPOUND | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| EP-0931060-A1 | SUBSTITUTED N- (AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999031491-A1 | METHOD AND REAGENTS FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999020275-A1 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999000356-A1 | SUBSTITUTED N-[(AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233409-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF | ADORA3, HTR3C, TRPV3 | ALDH1A1 1525/4885HPGD 2192/4885MAPT 4028/4885 |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | ALDH1A1 2218/4885HPGD 1720/4885MAPT 4525/4885 |
| US-20170000773-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF | HTR6, HTR3C, HTR3B | ALDH1A1 1667/4885HPGD 3559/4885MAPT 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.